<DOC>
	<DOCNO>NCT01716754</DOCNO>
	<brief_summary>This study assess effect asthma control different dose level regimens QGE031 asthma patient inadequately control inhaled steroid beta-2 agonist medication . Safety assess also . Comparison placebo omalizumab . Information study plan support design future study .</brief_summary>
	<brief_title>Efficacy Safety QGE031versus Placebo Omalizumab Patients Aged 18-75 Years With Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Omalizumab</mesh_term>
	<criteria>Key A diagnosis allergic asthma , uncontrolled current medication . History least 1 asthma exacerbation last 1 year Forced Expiratory Volume one second ( FEV1 ) ≥ 40 % ≤ 80 % predict normal value ; reversibility follow administration bronchodilator must also demonstrate ( historical positive reversibility bronchoprovocation result use ) . Key Baseline IgE level body weight outside omalizumab dose table . Use tobacco product within previous 6 month ( Social occasional smoker may include ) . Recent asthma attack/exacerbation asthma worsening/ respiratory infection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>asthma</keyword>
	<keyword>asthma control</keyword>
	<keyword>allergy</keyword>
	<keyword>atopic</keyword>
	<keyword>IgE</keyword>
	<keyword>double-blind</keyword>
	<keyword>placebo</keyword>
	<keyword>omalizumab</keyword>
</DOC>